| Radiotherapy modality | 3D CRT | VMAT (IMRT) | TOTAL | |
| n = | 9 patients (37.5%) | 15 patients (62.5%) | 24 patients (100%) | |
| Age (range) | 9 - 17 years | 12 - 17 years | 9 - 17 years | |
| Average | 13.7 | 14.3 | 14.1 | |
| Tumour size | 22 - 71 mm2 | 21 - 88 mm2 | 21 - 88 mm2 | |
| Median | 45 mm2 | 49 mm2 | 46.5 mm2 | |
| Chandler* | CS III | 4 (44.4%) | 5 (33.3%) | 9 (37.5%) |
| CS IV | 5 (55.5%) | 10 (66.6%) | 15 (62.5%) | |
| Functional state (Initial) | Karnofsky > 90% | 8 (88.8%) | 14 (93.3%) | 22 (91.66%) |
| Karnofsky < 90% | 1 (11.2%) | 1 (6.7%) | 2 (8.33%) | |
| Symptoms (Initial) | Nasal Obstruction | 9 (100%) | 15 (100%) | 24 (100%) |
| Epistaxis | 2 (22.2%) | 10 (66.6%) | 12 (50%) | |
| Surgical Management | Subtotal Resection | 5 (55.5%) | 11 (73.3%) | 16 (66.6%) |
| Complete Resection | 1 (11.2%) | 0 (0%) | 1 (4.2%) | |
| Non-surgical candidates | 3 (33.3%) | 4 (26.7%) | 7 (29.2%) | |
| Embolization | Given | 3 (33.3%) | 6 (40%) | 9 (37.5%) |
| Not Given | 6 (66.7%) | 9 (60%) | 15 (62.5%) | |
| Radiotherapy Dose | Less than 50 Gy | 5 (55.5%) | 2 (13.3%) | 7 (29.16%) |
| Equal to or greater than 50 Gy | 4 (44.5%) | 13 (86.7%) | 17 (70.83%) | |